Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Colchicine for Primary Hepatic Malignant Tumors
NCT04264260Phase 2Completed
- Sponsor
- Kaohsiung Medical University Chung-Ho Memorial Hospital
- Start
- Dec 2019
- Primary completion
- May 2025
- Modality
- Nucleic Acid-Directed Small Molecules, Classical Binding Small Molecules, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of colchicine in hepatocellular carcinoma (HCC), intrahepatic cholangiocarcinoma (ICC), combined hepatocellular-cholangiocarcinoma (cHCC-CCA) and 1 more, sponsored by Kaohsiung Medical University Chung-Ho Memorial Hospital. Primary endpoint: Overall Survival at 31 months. Started Dec 2019; status: completed.
02
Drugs
colchicine
03
Conditions
hepatocellular carcinoma (HCC)intrahepatic cholangiocarcinoma (ICC)combined hepatocellular-cholangiocarcinoma (cHCC-CCA)Primary hepatic malignancy
Beyond the preview
Go deeper on NCT04264260.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04264260.